Insomnia in Patients with Depression

No abstract is available for this paper.

• Publication year

  2009

• Venue

  CNS Drugs

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2165/00023210-200923040-00004PMID 19374460
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Ethical aspects of clinical trials in patients with multiple sclerosis].

  2009cited by this paper
• The epidemiology of insomnia: associations with physical and mental health. The HUNT-2 study.

  2009cited by this paper
• Is insomnia a perpetuating factor for late-life depression in the IMPACT cohort?

  2008cited by this paper
• Sleep disturbance and depression recurrence in community-dwelling older adults: a prospective study.

  2008cited by this paper
• Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?

  2008cited by this paper
• Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea.

  2008cited by this paper
• Low-dose sublingual zolpidem tartrate is associated with dose-related improvement in sleep onset and duration in insomnia characterized by middle-of-the-night (MOTN) awakenings.

  2008cited by this paper
• Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.

  2008cited by this paper
• Adolescent insomnia as a risk factor for early adult depression and substance abuse.

  2008cited by this paper
• Slow-wave sleep and the risk of type 2 diabetes in humans

  2008cited by this paper
• Association Between Depressive Symptoms and Sleep Disturbances in Community‐Dwelling Older Men

  2008cited by this paper
• A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder

  2008cited by this paper
• Prevalence, course, and comorbidity of insomnia and depression in young adults.

  2008cited by this paper
• Polysomnographic Study of Intermittent Zolpidem Treatment in Primary Sleep Maintenance Insomnia

  2008cited by this paper
• Sleep disturbance preceding completed suicide in adolescents.

  2008cited by this paper
• Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia.

  2008cited by this paper
• Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: Improvements in quality of life and quality of sleep.

  2008cited by this paper
• Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.

  2007cited by this paper
• Diurnal variation in regional brain glucose metabolism in depression.

  2007cited by this paper
• Coadministration of Modafinil and a Selective Serotonin Reuptake Inhibitor From the Initiation of Treatment of Major Depressive Disorder With Fatigue and Sleepiness: A Double-Blind, Placebo-Controlled Study

  2007cited by this paper
• Major depressive disorder, sleep EEG and agomelatine: an open-label study.

  2007cited by this paper
• Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.

  2007cited by this paper
• Efficacy of mirtazapine in obstructive sleep apnea syndrome.

  2007cited by this paper
• Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia.

  2007cited by this paper
• Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.

  2007cited by this paper
• Long-term nightly treatment with indiplon in adults with primary insomnia: results of a double-blind, placebo-controlled, 3-month study.

  2007cited by this paper
• Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

  2007cited by this paper
• A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression.

  2007cited by this paper
• Insomnia associated with valerian and melatonin usage in the 2002 National Health Interview Survey.

  2007cited by this paper
• Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder*

  2007cited by this paper
• Patterns of depressive symptom response in duloxetine‐treated outpatients with mild, moderate or more severe depression

  2007cited by this paper
• Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia.

  2007cited by this paper
• Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents.

  2007cited by this paper
• A systematic review of valerian as a sleep aid: safe but not effective.

  2007cited by this paper
• Efficacy and tolerability of indiplon in older adults with primary insomnia.

  2007cited by this paper
• A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder.

  2007cited by this paper
• Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2

  2007cited by this paper
• Relative Abuse Liability of Indiplon and Triazolam in Humans: A Comparison of Psychomotor, Subjective, and Cognitive Effects

  2007cited by this paper
• Sleep disorders and suicidal ideation in patients with depressive disorder.

  2007cited by this paper
• Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine).

  2007cited by this paper
• A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia

  2007cited by this paper
• Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment‐resistant depression

  2007cited by this paper
• Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations.

  2007cited by this paper
• Dose-response effects of cognitive-behavioral insomnia therapy: a randomized clinical trial.

  2007cited by this paper
• Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression

  2007cited by this paper
• Effect of tiagabine on sleep in elderly subjects with primary insomnia: a randomized, double-blind, placebo-controlled study.

  2006cited by this paper
• Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.

  2006cited by this paper
• Psychological and behavioral treatment of insomnia:update of the recent evidence (1998-2004).

  2006cited by this paper
• Treatment-resistant depression.

  2006cited by this paper
• An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia.

  2006cited by this paper
• Tiagabine increases slow-wave sleep in a dose-dependent fashion without affecting traditional efficacy measures in adults with primary insomnia.

  2006cited by this paper
• Sleep Microarchitecture in Childhood and Adolescent Depression: Temporal Coherence

  2006cited by this paper
• Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis.

  2006cited by this paper
• Polysomnographic and Symptomatological Analyses of Major Depressive Disorder Patients Treated with Mirtazapine

  2006cited by this paper
• Sleeping in? The impact of age and depressive sub-type on hypersomnia.

  2006cited by this paper
• Efficacy and tolerability of modified-release indiplon in elderly patients with chronic insomnia: results of a 2-week double-blind, placebo-controlled trial.

  2006cited by this paper
• A Double-blind, Placebo- and Flurazepam-controlled Investigation of the Residual Psychomotor and Cognitive Effects of Modified Release Zolpidem in Young Healthy Volunteers

  2006cited by this paper
• Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

  2006cited by this paper
• Mirtazapine Orally Disintegrating Tablets Versus Venlafaxine Extended Release: A Double-blind, Randomized Multicenter Trial Comparing the Onset of Antidepressant Response in Patients With Major Depressive Disorder

  2006cited by this paper
• Sleep and residual sedation after administration of zaleplon, zolpidem, and placebo during experimental middle-of-the-night awakening.

  2006cited by this paper
• Practice parameters for the psychological and behavioral treatment of insomnia: an update. An american academy of sleep medicine report.

  2006cited by this paper
• Changes of Sleep Architecture, Spectral Composition of Sleep EEG, the Nocturnal Secretion of Cortisol, ACTH, GH, Prolactin, Melatonin, Ghrelin, and Leptin, and the DEX-CRH Test in Depressed Patients during Treatment with Mirtazapine

  2006cited by this paper
• Modafinil for Atypical Depression: Effects of Open-label and Double-blind Discontinuation Treatment

  2006cited by this paper
• Diagnosing Major Depressive Disorder I: A Psychometric Evaluation of the DSM-IV Symptom Criteria

  2006cited by this paper
• The value of quantitative electroencephalography in clinical psychiatry: a report by the Committee on Research of the American Neuropsychiatric Association.

  2006cited by this paper
• A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers.

  2006cited by this paper
• Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.

  2006cited by this paper
• Tiagabine is associated with sustained attention during sleep restriction: evidence for the value of slow-wave sleep enhancement?

  2006cited by this paper
• Critical role of M3 muscarinic receptor in insulin secretion: implications for psychopharmacology.

  2006cited by this paper
• Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.

  2006cited by this paper
• Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits

  2005cited by this paper
• Changes in sleep polygraphic variables and clinical state in depressed patients during treatment with citalopram

  2005cited by this paper
• Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects

  2005cited by this paper
• Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients

  2005cited by this paper
• Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial.

  2005cited by this paper
• An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia.

  2005cited by this paper
• Phase‐shifts of 24‐h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men

  2005cited by this paper
• A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness.

  2005cited by this paper
• Chapter 116 – Monitoring and Staging Human Sleep

  2005cited by this paper
• Can social factors explain sex differences in insomnia? Findings from a national survey in Taiwan

  2005cited by this paper
• Depression in diabetic patients: the relationship between mood and glycemic control.

  2005cited by this paper
• Sleep Laboratory Study on Single and Repeated Dose Effects of Paroxetine, Alprazolam and Their Combination in Healthy Young Volunteers

  2005cited by this paper
• Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence.

  2005cited by this paper
• Antidepressants and periodic leg movements of sleep.

  2005cited by this paper
• Next-day residual effects of hypnotics in DSM-IV primary insomnia: a driving simulator study with simultaneous electroencephalogram monitoring

  2005cited by this paper
• The effect of escitalopram on sleep problems in depressed patients

  2005cited by this paper
• Alterations in regional cerebral glucose metabolism across waking and non-rapid eye movement sleep in depression.

  2005cited by this paper
• Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries.

  2005cited by this paper
• Functional neuroimaging evidence for hyperarousal in insomnia.

  2004cited by this paper
• Zolpidem is not superior to temazepam with respect to rebound insomnia: a controlled study.

  2004cited by this paper
• Response, partial response, and nonresponse in primary care treatment of depression.

  2004cited by this paper
• Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study

  2004cited by this paper
• ATONIA OF SKELETAL MUSCLES IS ONE OF THE CARDINAL FEATURES OF RAPID EYE MOVEMENT (REM) SLEEP

  2004cited by this paper
• Treatment of insomnia associated with clinical depression.

  2004cited by this paper
• Comparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients

  2004cited by this paper
• Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison.

  2004cited by this paper
• Minor depression: risk profiles, functional disability, health care use and risk of developing major depression.

  2004cited by this paper
• Daytime sleepiness and insomnia as correlates of depression.

  2004cited by this paper
• Adjunctive modafinil at initiation of treatment with a selective serotonin reuptake inhibitor enhances the degree and onset of therapeutic effects in patients with major depressive disorder and fatigue.

  2004cited by this paper
• Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.

  2004cited by this paper

• The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.

  2025cites this paper
• Evaluation of alpha neurofeedback training to enhance sleep in remitted depression and anxiety sufferers with persistent insomnia.

  2025cites this paper
• Effectiveness of Sleep Hygiene Programs on Sleep Quality of Patients With Mild Traumatic Brain Injury: A Randomized Controlled Trial

  2025cites this paper
• Acupuncture for comorbid depression and insomnia in perimenopause: A feasibility patient-assessor-blinded, randomized, and sham-controlled clinical trial

  2023cites this paper
• Cognitive Behavioral Therapy for Chronic Insomnia in Outpatients with Major Depression—A Randomised Controlled Trial

  2022cites this paper
• The characteristics of discharge prescriptions including pro re nata psychotropic medications for patients with schizophrenia and major depressive disorder from the survey of the “Effectiveness of guidelines for dissemination and education in psychiatric treatment (EGUIDE)” project

  2022cites this paper
• The Role of Acupuncture in the Management of Insomnia as a Major or Residual Symptom Among Patients With Active or Previous Depression: A Systematic Review and Meta-Analysis

  2022cites this paper
• Antidepressants and sleep

  2021cites this paper
• Sleep Disturbances Among Patients in Primary Care: Psychiatric Practice

  2018cites this paper
• The Science and Art of Prescribing for Insomnia

  2018cites this paper
• Schlafstörungen in der Psychiatrie und Psychotherapie

  2016cites this paper
• Biosynthesis of Serotonin in the Brain of Rats under Conditions of Obesity Induced By Compatible Consumption of High Calorie Diet And 10% Fructose Solution as A Possible Target For Obesity Prevention. -

  2015cites this paper
• Effects of a Multi-Component Behavioral Intervention (MCI) for Insomnia on Depressive and Insomnia Symptoms in Individuals with High and Low Depression

  2015cites this paper
• Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation.

  2015cites this paper
• Short-Term Effects of Electroconvulsive Therapy on Subjective and Actigraphy-Assessed Sleep Parameters in Severely Depressed Inpatients

  2015cites this paper
• Poor actigraphic and self-reported sleep patterns predict delinquency and daytime impairment among at-risk adolescents.

  2015cites this paper
• Neuroplasticity and the next wave of antidepressant strategies

  2013cites this paper
• The Genetic and Environmental Structure of the Covariation Among the Symptoms of Insomnia, Fatigue, and Depression in Adult Females

  2012cites this paper
• Guía de atención integral para la detección temprana y diagnóstico del episodio depresivo y trastorno depresivo recurrente en adultos. Atención integral de los adultos con diagnóstico de episodio depresivo o trastorno depresivo recurrente

  2012cites this paper
• The Effects of Mirtazapine on Sleep in Patients with Major Depressive Disorder

  2012cites this paper
• Changes of Sleep Adaptation in Hospitalized Patients with Depression

  2012cites this paper
• Sleep disturbances in Parkinson’s disease patients and management options

  2011cites this paper
• Comorbid Insomnia: Reciprocal Relationships and Medication Management

  2010cites this paper
• [Psychiatric and psychological complications in obstructive sleep apnea syndrome].

  2010cites this paper
• Pathophysiology of Sleep Disorders

  2010cites this paper
• Brain serotonergic circuitries

  2010cites this paper
• Cognitive behavioral therapy alone and with medication for persistent insomnia.

  2009cites this paper
• Pharmacotherapy of Major Depressive Disorder: Focus on Duloxetine

  2009cites this paper